First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor by Vidya Perera, Zhaoqing Wang, Joseph Luettgen, Danshi Li, Mary DeSouza, Michael Cerra, Dietmar Seiffert

Connect to this object online.

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder by Samira J. Merali, Wonkyung Byon, Yogesh T. Patel, Amira Elsrougy, David Marchisin, Vidya Perera, Weidong Chen, Bing He, Bindu Murthy

Connect to this object online.

Recommendation of mavacamten posology by model‐based analyses in adults with obstructive hypertrophic cardiomyopathy by Samira Merali, David H. Salinger, Maria Palmisano, Amy J. Sehnert, Neelima Thanneer, Hyunmoon Back, Julie D. Seroogy, Daniel D. Gretler, Amit Roy, Vidya Perera

Connect to this object online.

Absolute oral bioavailability of milvexian spray‐dried dispersion formulation under fasted and fed conditions in healthy adult participants: An intravenous microtracer approach by Praneeth Jarugula, Sharif Soleman, Hyunmoon Back, Lisa J. Christopher, Dara Hawthorne, Ronald Aronson, Anh Bui, Angela Mirzac, Antoinette Ajavon‐Hartmann, Vidya Perera, Bindu Murthy, Samira Merali

Connect to this object online.

Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration by Peter Chang, Vidya Perera, David H. Salinger, Samira Merali, Neelima Thanneer, Hyunmoon Back, Julie D. Seroogy, Daniel D. Gretler, Amy J. Sehnert, Maria Palmisano, Amit Roy

Connect to this object online.